BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16369543)

  • 1. A role for the scaffolding adapter GAB2 in breast cancer.
    Bentires-Alj M; Gil SG; Chan R; Wang ZC; Wang Y; Imanaka N; Harris LN; Richardson A; Neel BG; Gu H
    Nat Med; 2006 Jan; 12(1):114-21. PubMed ID: 16369543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Gab2 in mammary tumorigenesis and metastasis.
    Ke Y; Wu D; Princen F; Nguyen T; Pang Y; Lesperance J; Muller WJ; Oshima RG; Feng GS
    Oncogene; 2007 Jul; 26(34):4951-60. PubMed ID: 17310989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
    Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
    Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer.
    Daly RJ; Gu H; Parmar J; Malaney S; Lyons RJ; Kairouz R; Head DR; Henshall SM; Neel BG; Sutherland RL
    Oncogene; 2002 Aug; 21(33):5175-81. PubMed ID: 12140767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
    Bentires-Alj M; Neel BG
    Cancer Res; 2007 Mar; 67(6):2420-4. PubMed ID: 17347513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T; Luoh SW
    Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression.
    Hardy S; Wong NN; Muller WJ; Park M; Tremblay ML
    Cancer Res; 2010 Nov; 70(21):8959-67. PubMed ID: 20841483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
    Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
    Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer.
    Mira A; Isella C; Renzulli T; Cantarella D; Martelli ML; Medico E
    Oncogene; 2009 Dec; 28(50):4444-55. PubMed ID: 19838208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
    Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
    Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
    Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
    Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth.
    Bertotti A; Comoglio PM; Trusolino L
    J Cell Biol; 2006 Dec; 175(6):993-1003. PubMed ID: 17158954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.
    Lanza-Jacoby S; Burd R; Rosato FE; McGuire K; Little J; Nougbilly N; Miller S
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6161-9. PubMed ID: 17062693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-opted integrin signaling in ErbB2-induced mammary tumor progression.
    Carraway KL; Sweeney C
    Cancer Cell; 2006 Aug; 10(2):93-5. PubMed ID: 16904607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
    Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-redundant roles of the Gab1 and Gab2 scaffolding adapters in VEGF-mediated signalling, migration, and survival of endothelial cells.
    Caron C; Spring K; Laramée M; Chabot C; Cloutier M; Gu H; Royal I
    Cell Signal; 2009 Jun; 21(6):943-53. PubMed ID: 19233262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
    Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
    Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor.
    Meng S; Chen Z; Munoz-Antonia T; Wu J
    Biochem J; 2005 Oct; 391(Pt 1):143-51. PubMed ID: 15952937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors.
    Hirose H; Ishii H; Mimori K; Ohta D; Ohkuma M; Tsujii H; Saito T; Sekimoto M; Doki Y; Mori M
    Oncol Rep; 2010 Jan; 23(1):35-43. PubMed ID: 19956862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.